Auxilium Biotechnologies has formally launched a medical trial for its proprietary NeuroSpan Bridge, a nerve-regeneration implant first bioprinted in area. The implant, created utilizing the corporate’s AMP-1 bioprinter aboard the Worldwide Area Station (ISS), is now being examined on sufferers with traumatic nerve accidents again on Earth.
This marks a serious second not only for Auxilium, however for bioprinting and regenerative medication. It’s the primary time a tool made utilizing space-based bioprinting is being utilized in a medical trial to assist restore motion and sensation in individuals with extreme nerve injury.
NeuroSpan Bridge is a small implant designed to information nerve regeneration after harm. Surgeons place it contained in the physique on the website of the broken nerve, and the system copies the pure construction of nerves utilizing tiny microchannels, which assist new nerve fibers develop in the correct course. It’s meant to hurry up therapeutic, scale back issues like persistent ache, and enhance general restoration.
The trial, known as Neurospan-1, has enrolled the primary affected person within the US and goals to incorporate 80 individuals. It’s going down at a number of main medical facilities, together with New York College Langone, the College of California, San Francisco (UCSF), the Ohio State College Wexner Medical Middle, and the San Antonio Orthopaedic Group (TSAOG). The examine is targeted on individuals with traumatic nerve accidents, like these brought on by automotive accidents or office accidents, and can check how nicely the implant works, how protected it’s, and the way it compares to present therapies.
“We’ve spent years creating a expertise with the potential to alter lives, and as we speak, we’re one step nearer to creating {that a} actuality,” mentioned Jacob Koffler, CEO of Auxilium.
From Orbit to Working Rooms
Probably the most hanging a part of the NeuroSpan Bridge story is the place it started: in orbit. In February 2025, Auxilium introduced that it had efficiently manufactured the implant aboard the ISS utilizing its AMP-1 bioprinter. The printer was constructed to function in microgravity, which permits for greater precision and extra complicated buildings than can typically be achieved on Earth.
By printing in area, the corporate was in a position to create implants with extraordinarily advantageous particulars, just like the microchannels that assist nerves develop again correctly, with out the danger of structural collapse brought on by gravity.
AMP-1 bioprinter. Picture courtesy of Auxilium Biotechnologies.
The AMP-1 bioprinter makes use of small, preloaded cartridges with organic supplies, taking lower than a minute of astronaut time per session. The printed implants are then despatched again to Earth to be used in trials like Neurospan-1.
“This represents a leap in technological innovation,” mentioned Isac Lazarovits, Director of Engineering at Auxilium. “With AMP-1 now operational, we’re advancing our biomanufacturing analysis and the event of regenerative medical units at an unprecedented tempo.”
Auxilium Biotechnologies 3D bioprinted eight implantable medical units for repairing nerve injury aboard the ISS. Picture courtesy of Enterprise Wire.
Why Area Bioprinting Issues
Bioprinting in area gives actual manufacturing advantages, particularly for implants constructed from gentle, dwelling, or complicated biomaterials. Based on the researchers, microgravity lets supplies settle extra evenly, serving to create higher shapes, extra secure buildings, and extra dependable efficiency within the physique.
This might open the door to new therapies for accidents that beforehand had restricted choices. For now, the printed implants shall be used on Earth, however the identical expertise could sometime assist astronauts recuperate from accidents throughout lengthy missions to the Moon or Mars.
Auxilium’s success additionally exhibits how space-based manufacturing, as soon as the area of enormous aerospace companies, has turn out to be extra accessible to smaller biotech corporations centered on fixing real-world medical issues.
Auxilium Biotechnologies 3D bio-printed perfusable vasculature aboard the ISS, demonstrating the power to print blood vessels. Picture courtesy of Enterprise Wire.
With the trial underway, the main target now could be on the outcomes. Auxilium hopes to show that the NeuroSpan Bridge may help sufferers recuperate quicker and with fewer long-term issues than with conventional grafts or nerve restore methods.
In the meantime, the corporate can also be trying on the sustainability facet of this. For the reason that NeuroSpan Bridge is constructed from metal-based supplies, any leftover powder from the printing course of is distributed again to Auxilium’s accomplice, International Superior Metals, for recycling. This creates a full closed-loop system, lowering waste and making manufacturing extra sustainable.
General, Auxilium’s trial proves that what began in orbit is now being examined on sufferers, marking a serious step for space-based bioprinting in real-world medication.
Subscribe to Our Electronic mail Publication
Keep up-to-date on all the most recent information from the 3D printing trade and obtain data and gives from third occasion distributors.
Add your 3D Fashions and get them printed shortly and effectively.
